Janneke C van den Bergen1, Monika Hiller2, Stefan Böhringer3, Linda Vijfhuizen4, Hendrika B Ginjaar4, Amina Chaouch5, Kate Bushby5, Volker Straub5, Mariacristina Scoto6, Sebahattin Cirak7, Véronique Humbertclaude8, Mireille Claustres8, Chiara Scotton9, Chiara Passarelli10, Hanns Lochmüller5, Francesco Muntoni6, Sylvie Tuffery-Giraud8, Alessandra Ferlini9, Annemieke M Aartsma-Rus2, Jan J G M Verschuuren1, Peter Ac 't Hoen2, Pietro Spitali2. 1. Department of Neurology, Leiden University Medical Center, Leiden, The Netherlands. 2. Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands. 3. Department of Medical Statistics and Bioinformatics, Leiden University Medical Center, Leiden, The Netherlands. 4. Department of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands. 5. Institute of Human Genetics, Newcastle University, International Centre for Life, Central Parkway, Newcastle upon Tyne, UK. 6. Dubowitz Neuromuscular Centre, University College London, London, UK. 7. Dubowitz Neuromuscular Centre, University College London, London, UK Children's National Medical Center, Research Center for Genetic Medicine, Washington DC, USA. 8. Laboratoire de Génétique de Maladies Rares, CHU Montpellier, Université Montpellier 1, UFR Médecine, and Inserm U827, Montpellier, France. 9. Department of Medical Sciences, Section of Microbiology and Medical Genetics, University of Ferrara, Ferrara, Italy. 10. Paediatric Hospital Bambino Gesù, Rome, Italy.
Abstract
OBJECTIVE: Duchenne muscular dystrophy (DMD) is characterised by progressive muscle weakness. It has recently been reported that single nucleotide polymorphisms (SNPs) located in the SPP1 and LTBP4 loci can account for some of the inter-individual variability observed in the clinical disease course. The validation of genetic association in large independent cohorts is a key process for rare diseases in order to qualify prognostic biomarkers and stratify patients in clinical trials. METHODS: Duchenne patients from five European neuromuscular centres were included. Information about age at wheelchair dependence and steroid use was gathered. Melting curve analysis of PCR fragments or Sanger sequencing were used to genotype SNP rs28357094 in the SPP1 gene in 336 patients. The genotype of SNPs rs2303729, rs1131620, rs1051303 and rs10880 in the LTBP4 locus was determined in 265 patients by mass spectrometry. For both loci, a multivariate analysis was performed, using genotype/haplotype, steroid use and cohort as covariates. RESULTS: We show that corticosteroid treatment and the IAAM haplotype of the LTBP4 gene are significantly associated with prolonged ambulation in patients with DMD. There was no significant association between the SNP rs28357094 in the SPP1 gene and the age of ambulation loss. CONCLUSIONS: This study underlines the importance of replicating genetic association studies for rare diseases in large independent cohorts to identify the most robust associations. We anticipate that genotyping of validated genetic associations will become important for the design and interpretation of clinical trials. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
OBJECTIVE:Duchenne muscular dystrophy (DMD) is characterised by progressive muscle weakness. It has recently been reported that single nucleotide polymorphisms (SNPs) located in the SPP1 and LTBP4 loci can account for some of the inter-individual variability observed in the clinical disease course. The validation of genetic association in large independent cohorts is a key process for rare diseases in order to qualify prognostic biomarkers and stratify patients in clinical trials. METHODS:Duchennepatients from five European neuromuscular centres were included. Information about age at wheelchair dependence and steroid use was gathered. Melting curve analysis of PCR fragments or Sanger sequencing were used to genotype SNP rs28357094 in the SPP1 gene in 336 patients. The genotype of SNPs rs2303729, rs1131620, rs1051303 and rs10880 in the LTBP4 locus was determined in 265 patients by mass spectrometry. For both loci, a multivariate analysis was performed, using genotype/haplotype, steroid use and cohort as covariates. RESULTS: We show that corticosteroid treatment and the IAAM haplotype of the LTBP4 gene are significantly associated with prolonged ambulation in patients with DMD. There was no significant association between the SNP rs28357094 in the SPP1 gene and the age of ambulation loss. CONCLUSIONS: This study underlines the importance of replicating genetic association studies for rare diseases in large independent cohorts to identify the most robust associations. We anticipate that genotyping of validated genetic associations will become important for the design and interpretation of clinical trials. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Authors: Sasha Bogdanovich; Thomas O B Krag; Elisabeth R Barton; Linda D Morris; Lisa-Anne Whittemore; Rexford S Ahima; Tejvir S Khurana Journal: Nature Date: 2002-11-28 Impact factor: 49.962
Authors: Ahlke Heydemann; Ermelinda Ceco; Jackie E Lim; Michele Hadhazy; Pearl Ryder; Jennifer L Moran; David R Beier; Abraham A Palmer; Elizabeth M McNally Journal: J Clin Invest Date: 2009-11-02 Impact factor: 14.808
Authors: P Bernasconi; E Torchiana; P Confalonieri; R Brugnoni; R Barresi; M Mora; F Cornelio; L Morandi; R Mantegazza Journal: J Clin Invest Date: 1995-08 Impact factor: 14.808
Authors: J R Mendell; R T Moxley; R C Griggs; M H Brooke; G M Fenichel; J P Miller; W King; L Signore; S Pandya; J Florence Journal: N Engl J Med Date: 1989-06-15 Impact factor: 91.245
Authors: Yong Li; William Foster; Bridget M Deasy; Yisheng Chan; Victor Prisk; Ying Tang; James Cummins; Johnny Huard Journal: Am J Pathol Date: 2004-03 Impact factor: 4.307
Authors: Cameron N Gundry; Steven F Dobrowolski; Y Ranae Martin; Thomas C Robbins; Lyle M Nay; Nathan Boyd; Thomas Coyne; Mikeal D Wall; Carl T Wittwer; David H-F Teng Journal: Nucleic Acids Res Date: 2008-04-29 Impact factor: 16.971
Authors: Utkarsh J Dang; Michael Ziemba; Paula R Clemens; Yetrib Hathout; Laurie S Conklin; Eric P Hoffman Journal: Hum Mol Genet Date: 2020-08-29 Impact factor: 6.150
Authors: Luca Bello; Heather Gordish-Dressman; Lauren P Morgenroth; Erik K Henricson; Tina Duong; Eric P Hoffman; Avital Cnaan; Craig M McDonald Journal: Neurology Date: 2015-08-26 Impact factor: 9.910
Authors: Annemieke Aartsma-Rus; Alessandra Ferlini; Elizabeth M McNally; Pietro Spitali; H Lee Sweeney Journal: Neuromuscul Disord Date: 2017-10-26 Impact factor: 4.296
Authors: Luca Bello; Kevin M Flanigan; Robert B Weiss; Pietro Spitali; Annemieke Aartsma-Rus; Francesco Muntoni; Irina Zaharieva; Alessandra Ferlini; Eugenio Mercuri; Sylvie Tuffery-Giraud; Mireille Claustres; Volker Straub; Hanns Lochmüller; Andrea Barp; Sara Vianello; Elena Pegoraro; Jaya Punetha; Heather Gordish-Dressman; Mamta Giri; Craig M McDonald; Eric P Hoffman Journal: Am J Hum Genet Date: 2016-10-13 Impact factor: 11.025
Authors: Natassia M Vieira; Janelle M Spinazzola; Matthew S Alexander; Yuri B Moreira; Genri Kawahara; Devin E Gibbs; Lillian C Mead; Sergio Verjovski-Almeida; Mayana Zatz; Louis M Kunkel Journal: Proc Natl Acad Sci U S A Date: 2017-05-22 Impact factor: 11.205
Authors: Andy H Vo; Kayleigh A Swaggart; Anna Woo; Quan Q Gao; Alexis R Demonbreun; Katherine S Fallon; Mattia Quattrocelli; Michele Hadhazy; Patrick G T Page; Zugen Chen; Ascia Eskin; Kevin Squire; Stanley F Nelson; Elizabeth M McNally Journal: Hum Mol Genet Date: 2019-01-15 Impact factor: 6.150
Authors: Charlotte S Van Dorn; Michael D Puchalski; Hsin-Yi Weng; Steven B Bleyl; Russell J Butterfield; Richard V Williams Journal: Cardiol Young Date: 2018-05-16 Impact factor: 1.093